{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:55:23Z","timestamp":1791474923602,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The influence of newer glucose-lowering agents on venous thromboembolism (VTE) risk has important therapeutic implications. This meta-analysis compared sodium-glucose cotransporter-2 inhibitors (SGLT2\u2014i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) with dipeptidyl peptidase-4 inhibitors (DPP-4i) and evaluated head-to-head SGLT2i versus GLP1-RA comparisons. Eligible studies enrolled adults with diabetes and reported adjusted relative risks for VTE, pulmonary embolism (PE), or deep vein thrombosis (DVT) using new-user cohort, target-trial emulation, nested case\u2013control, or randomized controlled designs. Pooled estimates were derived using inverse-variance meta-analysis on the log scale, with random-effects sensitivity analyses. Six studies met inclusion criteria, all of moderate risk of bias. Compared with DPP-4i, both SGLT2\u2014i (HR 0.72; 95% CI 0.62\u20130.82) and GLP1-RA (HR 0.78; 95% CI 0.73\u20130.83) were associated with significantly reduced VTE risk, whereas no difference was observed between SGLT2\u2014i and GLP1-RA (HR 1.02; 95% CI 0.84\u20131.23). Component analyses were directionally consistent: for PE, SGLT2\u2014i versus DPP-4i HR 0.44 (95% CI 0.30\u20130.64) and GLP1-RA versus DPP-4i HR 0.74 (95% CI 0.68\u20130.82); for DVT, SGLT2\u2014i versus DPP-4i HR 0.82 (95% CI 0.68\u20130.99) and GLP1-RA versus DPP-4i HR 0.81 (95% CI 0.75\u20130.88). In adults with diabetes, SGLT2\u2014i and GLP1-RA were each associated with a lower risk of VTE compared with DPP-4i, while head-to-head comparisons showed no clear difference and were limited by imprecision. These findings should be interpreted with caution given the limited evidence base. Overall, they suggest that concerns regarding VTE risk should not be a primary driver of treatment selection between these agents in clinical practice.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration:<\/jats:italic>\n                    PROSPERO CRD4201149607.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>In a meta-analysis of six observational studies, both SGLT2 inhibitors and GLP-1 receptor agonists were associated with a lower risk of venous thromboembolism compared with DPP-4 inhibitors, while no significant difference was observed between SGLT2 inhibitors and GLP-1 receptor agonists in head-to-head comparisons.<\/jats:p>","DOI":"10.1007\/s11739-026-04363-5","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:44:26Z","timestamp":1778093066000},"page":"1455-1468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-7790","authenticated-orcid":false,"given":"Andrea","family":"Boccatonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Simion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Brighenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"D\u2019Ardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"6","key":"4363_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00592-015-0746-8","volume":"52","author":"F Pomero","year":"2015","unstructured":"Pomero F, Di Minno MN, Fenoglio L, Gianni M, Ageno W, Dentali F (2015) Is diabetes a hypercoagulable state? A critical appraisal. Acta Diabetol 52(6):1007\u20131016. https:\/\/doi.org\/10.1007\/s00592-015-0746-8","journal-title":"Acta Diabetol"},{"issue":"42","key":"4363_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035329","volume":"102","author":"C Ding","year":"2023","unstructured":"Ding C, Guo C, Du D, Gong X, Yuan Y (2023) Association between diabetes and venous thromboembolism: a systematic review and meta-analysis. Medicine (Baltimore) 102(42):e35329. https:\/\/doi.org\/10.1097\/md.0000000000035329","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4363_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2014.11.003","volume":"135","author":"J Bai","year":"2015","unstructured":"Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z (2015) Diabetes is associated with increased risk of venous thromboembolism: a systematic review and meta-analysis. Thromb Res 135(1):90\u201395. https:\/\/doi.org\/10.1016\/j.thromres.2014.11.003","journal-title":"Thromb Res"},{"key":"4363_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2015.10.019","volume":"111","author":"EJ Bell","year":"2016","unstructured":"Bell EJ, Folsom AR, Lutsey PL et al (2016) Diabetes mellitus and venous thromboembolism: a systematic review and meta-analysis. Diabetes Res Clin Pract 111:10\u201318. https:\/\/doi.org\/10.1016\/j.diabres.2015.10.019","journal-title":"Diabetes Res Clin Pract"},{"key":"4363_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejim.2015.10.001","volume":"28","author":"K Gariani","year":"2016","unstructured":"Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C (2016) Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med 28:52\u201358. https:\/\/doi.org\/10.1016\/j.ejim.2015.10.001","journal-title":"Eur J Intern Med"},{"issue":"1","key":"4363_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/circulationaha.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117(1):93\u2013102. https:\/\/doi.org\/10.1161\/circulationaha.107.709204","journal-title":"Circulation"},{"issue":"1","key":"4363_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1055\/s-0040-1715444","volume":"121","author":"L Xin","year":"2021","unstructured":"Xin L, Sun S, Wang J, Lu W, Wang T, Tang H (2021) Dipeptidyl peptidase 4 inhibitors and venous thromboembolism risk in patients with type 2 diabetes: a meta-analysis of cardiovascular outcomes trials. Thromb Haemost 121(1):106\u2013108. https:\/\/doi.org\/10.1055\/s-0040-1715444","journal-title":"Thromb Haemost"},{"issue":"1","key":"4363_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3174","volume":"36","author":"A Wang","year":"2020","unstructured":"Wang A, Yang K, Wang T, Zhang N, Tang H, Feng X (2020) Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 36(1):e3174. https:\/\/doi.org\/10.1002\/dmrr.3174","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"4363_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1055\/a-2546-0353","volume":"51","author":"Q Chen","year":"2025","unstructured":"Chen Q, Anijs RJS, Verlaan JPL, Scheres LJJ, Klok FA, Cannegieter SC (2025) Novel antidiabetic drugs and risk of venous thromboembolism: a literature review. Semin Thromb Hemost 51(7):756\u2013767. https:\/\/doi.org\/10.1055\/a-2546-0353","journal-title":"Semin Thromb Hemost"},{"key":"4363_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.08.003","author":"AE Seddio","year":"2025","unstructured":"Seddio AE, Vasudevan RS, Gouzoulis MJ, Ansah-Twum JK, Grauer JN, Rubin LE (2025) As few as three months of preoperative semaglutide exposure prior to total knee arthroplasty is associated with reduced postoperative adverse events in patients who have type II diabetes. J Arthroplasty. https:\/\/doi.org\/10.1016\/j.arth.2025.08.003","journal-title":"J Arthroplasty"},{"issue":"2","key":"4363_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1160\/th16-03-0176","volume":"116","author":"F Santilli","year":"2016","unstructured":"Santilli F, Marchisio M, Lanuti P, Boccatonda A, Miscia S, Dav\u00ec G (2016) Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost 116(2):220\u2013234. https:\/\/doi.org\/10.1160\/th16-03-0176","journal-title":"Thromb Haemost"},{"issue":"3","key":"4363_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2011.11.052","volume":"129","author":"N Vazzana","year":"2012","unstructured":"Vazzana N, Ranalli P, Cuccurullo C, Dav\u00ec G (2012) Diabetes mellitus and thrombosis. Thromb Res 129(3):371\u2013377. https:\/\/doi.org\/10.1016\/j.thromres.2011.11.052","journal-title":"Thromb Res"},{"key":"4363_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prostaglandins.2015.05.002","volume":"120","author":"F Santilli","year":"2015","unstructured":"Santilli F, Simeone P, Liani R, Dav\u00ec G (2015) Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat 120:28\u201339. https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.05.002","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"10","key":"4363_CR14","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/bloodadvances.2025015871","volume":"9","author":"CH Chiang","year":"2025","unstructured":"Chiang CH, Song J, Chang YC et al (2025) Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation. Blood Adv 9(10):2410\u20132418. https:\/\/doi.org\/10.1182\/bloodadvances.2025015871","journal-title":"Blood Adv"},{"key":"4363_CR15","doi-asserted-by":"publisher","first-page":"1669685","DOI":"10.3389\/fmed.2025.1669685","volume":"12","author":"A Battistoni","year":"2025","unstructured":"Battistoni A, Piras L, Tartaglia N, Carrano FM, De Vitis C, Barbato E (2025) Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection. Front Med (Lausanne) 12:1669685. https:\/\/doi.org\/10.3389\/fmed.2025.1669685","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4363_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103081","volume":"50","author":"F Ricci","year":"2025","unstructured":"Ricci F, Saraullo S, Boccatonda A et al (2025) Early prescription of SGLT2i for acute patient care: from current evidence to future directions. Curr Probl Cardiol 50(8):103081. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103081","journal-title":"Curr Probl Cardiol"},{"key":"4363_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.06.003","volume":"140","author":"D D'Ardes","year":"2025","unstructured":"D\u2019Ardes D, Ricci F, Simeone P, Boccatonda A, Santilli F (2025) Addressing unmet needs in the use of SGLT2 inhibitors in critical and acute care setting. Eur J Intern Med 140:106374. https:\/\/doi.org\/10.1016\/j.ejim.2025.06.003","journal-title":"Eur J Intern Med"},{"issue":"2","key":"4363_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/jcmm.17115","volume":"26","author":"Q Tian","year":"2022","unstructured":"Tian Q, Guo K, Deng J, Zhong Y, Yang L (2022) Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. J Cell Mol Med 26(2):540\u2013547. https:\/\/doi.org\/10.1111\/jcmm.17115","journal-title":"J Cell Mol Med"},{"key":"4363_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.020","author":"CH Chiang","year":"2025","unstructured":"Chiang CH, Chang YC, Yu CC et al (2025) Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. https:\/\/doi.org\/10.1016\/j.jtha.2025.06.020","journal-title":"J Thromb Haemost"},{"issue":"9","key":"4363_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.039446","volume":"14","author":"Y Liu","year":"2025","unstructured":"Liu Y, He L, Han S et al (2025) Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 14(9):e039446. https:\/\/doi.org\/10.1161\/jaha.124.039446","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"4363_CR21","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1111\/bcp.15787","volume":"89","author":"S Aloe","year":"2023","unstructured":"Aloe S, Filliter C, Salmasi S et al (2023) Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: a population-based cohort study. Br J Clin Pharmacol 89(9):2902\u20132914. https:\/\/doi.org\/10.1111\/bcp.15787","journal-title":"Br J Clin Pharmacol"},{"key":"4363_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjcard.2023.06.016","volume":"201","author":"T Patil","year":"2023","unstructured":"Patil T, Cook M, Hobson J, Kaur A, Lee A (2023) Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide veterans health administration observational cohort study. Am J Cardiol 201:281\u2013293. https:\/\/doi.org\/10.1016\/j.amjcard.2023.06.016","journal-title":"Am J Cardiol"},{"issue":"5","key":"4363_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.amjmed.2020.10.046","volume":"134","author":"N Schmedt","year":"2021","unstructured":"Schmedt N, Enders D, Walker J, Garbe E, Douros A (2021) Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study. Am J Med 134(5):606-613.e6. https:\/\/doi.org\/10.1016\/j.amjmed.2020.10.046","journal-title":"Am J Med"},{"issue":"2","key":"4363_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3739","volume":"40","author":"HR Tsai","year":"2024","unstructured":"Tsai HR, Lin YJ, Yeh JI et al (2024) Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: a nationwide population-based study and meta-analysis. Diabetes Metab Res Rev 40(2):e3739. https:\/\/doi.org\/10.1002\/dmrr.3739","journal-title":"Diabetes Metab Res Rev"},{"key":"4363_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"issue":"6","key":"4363_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17086","volume":"8","author":"M Lewis","year":"2025","unstructured":"Lewis M, Burrack N, Heymann A, Grossman A, Neuman T, Abuhasira R (2025) Sodium-glucose cotransporter 2 inhibitors, erythrocytosis, and thrombosis in adults with type 2 diabetes. JAMA Netw Open 8(6):e2517086. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17086","journal-title":"JAMA Netw Open"},{"issue":"2","key":"4363_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","volume":"4","author":"J Gregson","year":"2019","unstructured":"Gregson J, Kaptoge S, Bolton T et al (2019) Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 4(2):163\u2013173. https:\/\/doi.org\/10.1001\/jamacardio.2018.4537","journal-title":"JAMA Cardiol"},{"issue":"9","key":"4363_CR28","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1016\/j.jtha.2025.05.020","volume":"23","author":"R Xiang","year":"2025","unstructured":"Xiang R, Huang A, Stevens H et al (2025) Visceral adipose tissue demonstrates a stronger association with venous thromboembolism than body mass index. J Thromb Haemost 23(9):2883\u20132889. https:\/\/doi.org\/10.1016\/j.jtha.2025.05.020","journal-title":"J Thromb Haemost"},{"key":"4363_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171994","author":"N Panchagnula","year":"2024","unstructured":"Panchagnula N, Brasher WP (2024) Hyperglycemia and venous thromboembolism. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics14171994","journal-title":"Diagnostics"},{"issue":"17","key":"4363_CR30","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1161\/circulationaha.109.921460","volume":"121","author":"AG Holst","year":"2010","unstructured":"Holst AG, Jensen G, Prescott E (2010) Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 121(17):1896\u20131903. https:\/\/doi.org\/10.1161\/circulationaha.109.921460","journal-title":"Circulation"},{"issue":"5","key":"4363_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/aje\/kwab291","volume":"191","author":"T Sha","year":"2022","unstructured":"Sha T, Zhang Y, Li C et al (2022) Association of metformin use with risk of venous thromboembolism in adults with type 2 diabetes: a general-population-based cohort study. Am J Epidemiol 191(5):856\u2013866. https:\/\/doi.org\/10.1093\/aje\/kwab291","journal-title":"Am J Epidemiol"},{"issue":"10","key":"4363_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.107996","volume":"35","author":"J Sundstr\u00f6m","year":"2021","unstructured":"Sundstr\u00f6m J, Krist\u00f3fi R, \u00d6stlund O et al (2021) A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. J Diabetes Complications 35(10):107996. https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.107996","journal-title":"J Diabetes Complications"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04363-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:07:02Z","timestamp":1781262422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04363-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4363"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04363-5","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}